5 Boring Stocks With Exciting Dividends
I am somewhat amazed at what’s been going on in the market for the last week or so.
5 Best Shipping Stocks To Buy For 2015: Global X China Industrials (CHII)
Global X China Industrials ETF (the Fund) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S-BOX China Industrials Index (the Underlying Index). The Underlying Index is a free float adjusted, liquidity tested and market capitalization-weighted index that is designed to measure performance of the investable universe of companies in the Industrials sector of the Chinese economy, as defined by Structured Solutions AG. Global X Management Company, LLC serves as the investment adviser to the Fund. Advisors' Opinion:- [By pamatlarge]
Investors looking to short a particular sector can choose from several Global X long ETFs. The Global X China Consumer ETF (CHIQ) concentrates its investments in consumer cyclical goods and consumer defense goods. The Global X China Energy ETF (CHIE) primarily holds stocks in coal, oil and utility companies. The Global X China Financials ETF (CHIX) only invests in financial services companies and real estate companies. The Global X China Industrials ETF (CHII) holds stocks in industrial companies and basic materials companies. The Global X China Materials ETF (CHIM) invests in basic materials stocks. The Global X China Technology ETF (CHIB) holds technology stocks as the core of its investments. All of these ETFs are particularly sensitive to sector downturns and general economic contractions.
5 Best Shipping Stocks To Buy For 2015: Shire PLC (SHPG)
Shire plc (Shire), incorporated on January 28, 2008, is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in other therapeutic areas. As of December 31, 2012, the Company�� products included VYVANSE/VENVANSE (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), FOSRENOL (lanthanum carbonate), XAGRID (anagrelide hydrochloride), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant) and DERMAGRAFT(Human Fibroblast-Derived Dermal Substitute). As of December 31, 2012, the Company�� products under development included INTUNIV (extended release guanfacine), VYVANSE/VENVANSE (lisdexamfetamine dimesylate), INTUNIV, Guanfacine Carrier Wave, LIALDA (mesalamine)/MEZAVANT (mesalazine), RESOLOR (prucalopride), RESOLOR (prucalopride), SPD 557(M0003), XAGRID, VYVANSE (lisdexamfetamine dimesylate), REPLAGAL (agalsidase alfa), HGT-4510, HGT-2310, HGT-1410, HGT-1110, HGT-3010, and DERMAGRAFT. On January 31, 2012, the United States Food and Drug Administration approved VYVANSE for the maintenance treatment of ADHD in adults. In March 2013, it announced the acquisition Of Premacure AB. In January 2014, Shire Plc sold its DERMAGRAFT assets to Organogenesis Inc. In January 2014, Shire Plc acquired 79.5% interest in ViroPharma Inc.
VANSE/ VENVANSE
VYVANSE is a New Chemical Entity (NCE) and is the pro-drug stimulant for the treatment of ADHD, where the amino acid l-lysine is linked to d-amphetamine. VYVANSE is therapeutically inactive until metabolized in the body. The United Stat! es Food and Drug Administration approved VYVANSE as a once-daily treatment for children aged 6 to 12 with ADHD in February 2007, for adults in April 2008 and for adolescents aged 13 to 17 in November 2010. VYVANSE is available in the United States in six dosage strengths: 20 milligram, 30 milligram, 40 milligram, 50 milligram, 60 milligram and 70 milligram. Health Canada approved VYVANSE for the treatment of ADHD in pediatric patients aged 6 to 12 in February 2009, and for adolescents and adults in November 2010. In April 2012, ANVISA, the Brazilian health authority, granted marketing authorization approval for lisdexamfetamine dimesylate for the treatment of ADHD in children aged 6-12.
ADDERALL XR
ADDERALL XR is an extended release treatment for ADHD, which uses MICROTROL drug delivery technology and is designed to provide once-daily dosing. It is available in 5 milligram, 10 milligram, 15 milligram, 20 milligram, 25 milligram and 30 milligram capsules and can be administered either as a capsule or sprinkled on soft food. The United States Food and Drug Administration has approved ADDERALL XR as a once-daily treatment for children aged 6 to 12 with ADHD, for adults in and for adolescents aged 13 to 17. Teva Pharmaceutical Industries, Ltd. (Teva) and Impax Laboratories, Inc. (Impax) commenced commercial shipment of their authorized generic versions of ADDERALL XR in April and October 2009, respectively. Shire receives royalties from Impax�� sales of authorized generic ADDERALL XR.
INTUNIV
INTUNIV is a selective alpha-2A receptor agonist indicated for the treatment of ADHD. Alpha-2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signalling in the prefrontal cortex (Cell. 2007; 129:397-410). INTUNIV is non-scheduled and has no known potential for abuse or dependence. The United States Food and Drug Administration approved INTUNIV in September 2009, as a once-daily monotherapy treatment of ADHD in children and adolesce! nts aged ! 6 to 17. It is available in 1 milligram, 2 milligram, 3 milligram and 4 milligram tablets.
EQUASYM
Shire has acquired from UCB the worldwide rights (excluding the United States, Canada and Barbados) to EQUASYM (methylphenidate hydrochloride) IR and XL for the treatment of ADHD in children and adolescents aged 6 to 18. At December 31, 2012,EQUASYM XL was commercially available in 10 countries in 10mg, 20mg and 30mg strengths. EQUASYM XL is marketed in Mexico and South Korea under the trade name METADATE CD.
LIALDA/MEZAVANT
LIALDA is indicated for the induction ofmild to moderately active UC and for the maintenance of remission of UC. The addition of the indication for maintenance of remission of ulcerative colitis was approved by Health Canada in February 2011, and by the United States Food and Drug Administration in July 2011. LIALDA is once-daily oral formulation of mesalamine indicated for the induction and maintenance of remission. As of December 31, 2012, LIALDA/MEZAVANT (this product is marketed outside the United States as MEZAVANT) was commercially available in 19 countries either directly or through distributor arrangements.
PENTASA
PENTASA controlled release capsules are approved in the United States (marketed by Shire in the United States and by Ferring outside of the United States) and indicated for the induction of remission and for the treatment of patients with mild to moderately active ulcerative colitis. PENTASA is an ethylcellulose-coated, controlled release capsule formulation designed to release therapeutic quantities of mesalamine throughout the gastrointestinal tract. PENTASA is available in the United States in 250 milligram and 500 milligram capsules.
RESOLOR
RESOLOR (prucalopride), a 5-HT4 receptor agonists that stimulates gastrointestinal motility and acts primarily on different parts of the lower gastrointestinal tract (enterokinetic). In October 2009, RESOLOR was appr! oved by t! he EMA throughout the European Union as a once daily oral treatment for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. In July 2010, Swissmedic granted RESOLOR marketing authorization in Switzerland for the treatment of idiopathic chronic constipation in adults. RESOLOR is available in milligram and 2 milligram dose strengths, both for once-daily dosing. At December 31, 2012, RESOLOR was available in six European Union countries. Formulated as a chewable tablet, FOSRENOL is available in 500 milligram, 750 milligram and 1,000 milligram dosage strengths.
XAGRID
XAGRID (anagrelide hydrochloride) is marketed in Europe for the reduction of elevated platelet counts in at-risk ET patients. XAGRID has been granted orphan drug status in the European Union. In the United States, anagrelide hydrochloride is sold by the Company under the name AGRYLIN for the treatment of thrombocythemia secondary to a MPD.
REPLAGAL
REPLAGAL is for the treatment of Fabry disease. Fabry disease is a genetic disorder resulting from a deficiency in the activity of the lysosomal enzyme alpha-galactosidase A, which is involved in the breakdown of fats. REPLAGAL is a human alpha-galactosidase A protein made in human cells that replaces the deficient alpha-galactosidase A with an active enzyme to ameliorate certain clinical manifestations of Fabry disease. At December 31, 2012, REPLAGAL was approved in 46 countries.
ELAPRASE
ELAPRASE is a treatment for Hunter syndrome (also known as Mucopolysaccharidosis Type II or MPS II). Hunter syndrome is a genetic disorder mainly affecting males that interferes with the body's ability to break down and recycle waste substances called mucopolysaccharides, also known as glycosaminoglycans (GAGs). ELAPRASE was approved by the United States Food and Drug Administration and granted marketing authorization by the EMA for the long term treatment of patients with Hunter ! syndrome.! ELAPRASE has been granted orphan drug by both the United States Food and Drug Administration and the EMA. ELAPRASE received approval from the Ministry of Health, Labour and Welfare in Japan. At December 31, 2012, ELAPRASE was approved in 51 countries.
VPRIV
VPRIV is a treatment for Type 1 Gaucher disease. Gaucher disease is an inherited genetic disorder, which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase. VPRIV was approved by the United States Food and Drug Administration in February 2010, for the long-term treatment of patients with Type 1 Gaucher disease. The EMA approved the marketing authorization for the use of VPRIV in August 2010. VPRIV was authorized as an orphan medicine through the Centralised Procedure in Europe. At December 31, 2012, VPRIV was approved in 38 countries.
FIRAZYR
FIRAZYR is a peptide-based therapeutic developed for the symptomatic treatment of acute attacks of HAE. In July 2008 the EMA granted marketing authorization throughout the European Union for the use of FIRAZYR for the symptomatic treatment of acute attacks of HAE, and in May 2011 approved FIRAZYR for self-administration after training in subcutaneous injection technique by a healthcare professional. In August 2011, the United States Food and Drug Administration granted marketing approval for FIRAZYR in the United States for treatment of acute attacks of HAE in adults aged 18 and older. After injection training, patients may self-administer FIRAZYR. FIRAZYR has been granted orphan drug by both the United States Food and Drug Administration and the EMA. At December 31, 2012, FIRAZYR was approved in 38 countries globally.
DERMAGRAFT
DERMAGRAFT is a bio-engineered skin substitute that assists in restoring damaged tissue. DERMAGRAFT is indicated for use in the treatment of full-thickness Diabetic foot ulcers (DFU) greater than six weeks in duration, which extend through the dermis, but without tendon, muscle, joint capsu! le, or bo! ne exposure. DERMAGRAFT is approved by the United States Food and Drug Administration as a Class III medical device for the treatment of DFUs. DERMAGRAFT is also approved for the treatment of DFUs in South Africa, Israel and Singapore.
The Company competes with Shionogi & Co., Ltd., Janssen-Cilag, Novartis, Medice, Eli Lilly, Warner Chilcott, Synergy Pharmaceuticals, Inc., ARYx Therapeutics, Theravance, Inc., Sucampo Pharmaceuticals, Inc., Albireo, Actelion Ltd., Protalix BioTherapeutics Inc, Genzyme, CSL Behring, Pharming Group N.V., ViroPharma, Dyax Corporation, Organogenesis, Healthpoint, Soluble System, KCI, Smith & Nephew, Aurobindo and Apotex.
Advisors' Opinion:- [By Johanna Bennett]
Shares of ViroPharma (VPHM) spiked nearly 26% after the rare-disease company said it was being acquired by U.K. biopharmaceutical firm Shire (SHPG). Shire is paying $4.2 billion, or $50 a share, to ViroPharma. Shire�� ADRs rose 0.7%
- [By Jesse Solomon]
A flurry of acquisitions has already occurred in the past few years. Most recently, the Irish pharmaceutical conglomerate Shire (SHPG) bought Pennsylvania-based ViroPharma for $4.2 billion late last year. The deal gave Shire access to Cinryze, medicine for a rare blood disorder.
- [By MONEYMORNING]
On Monday, Dublin-based pharmaceutical firm Shire (Nasdaq ADR: SHPG) announced that it will buy Pennsylvania-based ViroPharma (Nasdaq: VPHM) for $4.2 billion in cash. The $50 per share purchase price is a 27% premium to Viropharma's Friday close and a 64% premium to the price when sale rumors first emerged this summer.
10 Best Machinery Stocks To Watch For 2015: Axxess Unlimited Inc (AXXU)
Axxess Unlimited, Inc., incorporated on June 8, 2000, is the holding company for the Axxess family of companies. The Axxess family of companies includes both vertically-integrated operating businesses and horizontally-integrated companies with each supported by a common software technology - the Axxess RISE Platform. The Company provides next-generation business intelligence for a range of businesses and organizations. It provides information-driven business solutions through interactive marketing, interactive technologies, application and product development, customer relationship management, business intelligence, portals and collaboration, and infrastructure solutions. Its companies include Axxess Digital (AxxuD), Axxess Apps (AxxuA) and Axxess Brands (AxxuB).
Axxess Digital
AxxuD is an interactive digital agency company. The Company relies on the core logic of the Axxess Unlimited RISE platform.
Axxess Apps
AxxuA is a software development company. The focus of AxxuA includes: enterprise applications, custom applications, cloud applications and mobile applications. The Company has software-as-a-service (SaaS) solutions and custom and mobile products available in the government services, automobile dealership, medical and consumer goods sectors.
Axxess Brands
AxxuB is a marketer and manufacturer of specialty brands in better-for-you and indulgent categories under a variety of Company owned and licensed brand names. AxxuB licenses brands and provides outsource management.
Advisors' Opinion:- [By James E. Brumley]
Even if you're one of the few reading this now, odds are good that you'd still never heard of Axxess Unlimited Inc. (OTCMKTS:AXXU) until the beginning of February. Prior to that, trading in AXXU was thin and uneventful. The evidence? Prior to February 4th, the average daily volume was less than 10,000 shares per day, and had been stuck right around the $0.20 mark since the middle of last year. Since February 4th, though, things have changed for the better. Since then, volume has been considerably stronger, and Axxess Unlimited shares have finally woken up and decided to forge ahead.
- [By CRWE]
Last Friday, WIZD remained (0.00%) +0.000 at $.200 at the close (ref. google finance August 23, 2013 ��Close).
Axxess Unlimited, Inc. previously reported the second quarter 2013 financial results for the period ending June 30, 2013.
Second quarter 2013 compared to second quarter 2012 results included:
Total Revenues up 330% to $272,775 compared to $63,392
Gross Profit grew 1076% to $193,961 compared to loss of $19,876
Operating Expenses were up 97% as the company continued to invest in R&D and channel rollout for Axxess products and technology.
Operating Net Income increased 103% to $3,118 compared to loss of $116,773
Six-month period 2013 compared to six-month period 2012 results included:Total Revenues up 305% to $518,485 compared to $128,161
Gross Profit grew 1212% to $352,532 compared to $26,868
Operating Expenses were up 80%
Operating Net Income increased 96% to a loss of $6,551 compared to a loss of $172,982 - [By James E. Brumley]
If the names Axxess Unlimited Inc. (OTCMKTS:AXXU) and MagneGas Corporation (NASDAQ:MNGA) ring a bell, it might be because yours truly posted some bullish thoughts on both names earlier this week. Although neither small cap stock had done everything they needed to do in order become a fully bullish trade at the time, both MNGA and AXXU have cleared those hurdles in the meantime. So, in case you forgot (or in case you missed the first look), an updated review of Axxess Unlimited and MagneGas is merited.
5 Best Shipping Stocks To Buy For 2015: Komatsu Ltd (KMTUY)
Komatsu Ltd. (Komatsu), incorporated in May 13, 1921, is a global company engaged in the manufacturing, development, marketing and sale of a range of industrial-use products and services. The manufacturing operations of Komatsu are conducted primarily at plants located in Japan, the United States, Brazil, the United Kingdom, Germany, Sweden, Italy, Indonesia, China, Thailand and India. Komatsu�� products are primarily sold under the Komatsu brand name and almost all of its sales and service activities are conducted through its sales subsidiaries and independent distributors who primarily sell products to retail dealers in their respective geographic area. Komatsu operates and competes in the six principal markets, such as Japan, the United States, Europe and Commonwealth of Independent States (CIS), China, Asia (excluding Japan and China) and Oceania and the Middle East and Africa. In May, 2009, Komatsu acquired the additional interest in Komatsu Australia Corporate Finance Pty. Ltd.
Construction, Mining and Utility Equipment
The Company offers various types of construction, mining and utility equipment, ranging from super-large machines capable of mining applications to general construction equipment and mini construction equipment for urban use. Komatsu�� range of products in this operating segment also includes a variety of attachments to be used with its products. Komatsu�� principal products include excavating equipment, loading equipment, grading and roadbed preparation equipment, hauling equipment, forestry equipment, tunneling machines, recycling equipment, industrial vehicles, other equipment, engines and components, casting products and logistics.
Industrial Machinery and Others
The Company�� Industrial Machinery and Others segment products are used by a range of businesses and include industrial machinery, such as forging and sheet metal machinery and other services. Komatsu�� principal products include metal forging and stampi! ng presses, sheet metal machines, machine tools, defense systems, temperature-control equipment and others.
The Company competes with Caterpillar Inc., Hitachi Construction Machinery Co., Ltd., Volvo Construction Equipment NV, CNH Global N.V., Hyundai Heavy Industries Co., Ltd., Doosan Infracore Co., Ltd. and Toyota Motor Corporation.
Advisors' Opinion:- [By Nicole Seghetti]
Dumped
Japanese industrial manufacturer Komatsu (NASDAQOTH: KMTUY ) recently picked up market share in China by outcompeting rival Caterpillar on price. But Fisher probably dumped Komatsu stock based partly on the company's shrinking profits resulting from falling demand in Asian nations such as China and Indonesia�. - [By Dan Carroll]
An up-and-down yen spurs an up-and-down market
Abe brought about stimulus in response to one of Japan's worst economic problems of the last half-century: more than two decades of a stagnant economy and deflation. Weakening the yen against other leading currencies would be a boon for leading Japanese exporters looking for an edge against overseas competition. Manufacturers such as Komatsu (NASDAQOTH: KMTUY ) have applauded the moves as they look to use a weak yen to grow profits. Komatsu alone projected 46% full-year profit growth this year thanks to the weak yen. - [By Dan Carroll]
That doesn't mean you should rush headfirst into any old Japanese stock on the hopes of a nationwide surge; as with all investing, picking the best stocks is the way to go. The country's top exporters have seen their stock rise and fall with the yen's volatility, but leading manufacturers such as Kubota (NASDAQOTH: KUBTY ) and Komatsu (NASDAQOTH: KMTUY ) are poised to ride a weaker yen higher to better compete against foreign rivals.
- [By Dan Carroll]
Fellow Japanese manufacturer Komatsu's (NASDAQOTH: KMTUY ) shares have slid more than 3% this past month, but like Kubota, this stock has blown up in 2013 and could be headed higher with a win by Abe and the LDP. However, there's risk in Komatsu's lofty 45% profit growth outlook in 2013: The company's the top manufacturer in China, but given the current slowdown plaguing the second-largest economy on Earth, Komatsu investors could be left disappointed. Komatsu's likely to see a strong uptick for the full year due to the weak yen -- particularly if Abe moves more aggressively after the elections -- but China's slump could make meeting optimistic projections a tall order.
5 Best Shipping Stocks To Buy For 2015: Covidien PLC (COV)
Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. It operates its businesses through three segments: Medical Devices, which includes the development, manufacture and sale of endomechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products; Pharmaceuticals, which includes the development, manufacture and distribution of specialty pharmaceuticals and active pharmaceutical ingredients, and Medical Supplies, SharpSafety products and original equipment manufacturer products. In May 2012, it acquired Newport Medical Instruments, Inc. In May 2012, it acquired superDimension, Ltd. In June 2012, the Company acquired Oridion Systems Ltd. In October 2012, its Mallinckrodt acquired CNS Therapeutics, Inc. In January 2013, the Company acquired CV Ingenuity. Advisors' Opinion:- [By Jon C. Ogg]
Covidien Ltd. (NYSE: COV) was started as Buy at Needham & Co.
Halliburton Co. (NYSE: HAL) was reinstated as Outperform and added to the U.S. Focus List with a new price target of $58 (versus $48.30 now) at Credit Suisse, and it was reiterated as Buy and the price target was raised to $63 from $58 by Sterne Agee.
- [By Dan Carroll]
Finally, Covidien (NYSE: COV ) has also entered the renal denervation race, although this company looks to be behind St. Jude and Medtronic as the leaders. Covidien purchased small-time renal denervation player Maya Medical last year for up to $170 million including milestone payouts, and it also received European approval for its OneShot renal denervation system last year. However, Covidien only launched the OneShot commercially in January, putting it back with Boston Scientific in racing to catch up with St. Jude and Medtronic's advance.
- [By Keith Speights]
Product recalls usually hurt companies. Covidien's (NYSE: COV ) shares were temporarily affected by the company's recall of surgical tools last year. Johnson & Johnson stock took a hit in 2010 and early 2011 partially due to recalls of several products.�
- [By Myra Ramdenbourg]
Covidien PLC (COV): EVP and CFO Charles J Dockendorff sold 90,730 Shares
On 03/28/2014, EVP and CFO Charles J Dockendorff sold 90,730 shares at an average price of $72.5. Covidien PLC has a market cap of $32.68 billion and its shares were traded at around $72.50. The company has a P/E ratio of 21.10 and P/S ratio of 3.28 with a dividend yield of 1.60%. Over the past 10 years, Covidien Plc had an annual average earnings growth of 6.60%.
No comments:
Post a Comment